priately identify the best treatment has become more important. The purpose of this analysis is to compare the rates of testing among HN patients on two key biomarker tests PD-L1 and HPV status in the US and 5 European (EU5) countries. MethodS: A retrospective medical chart review of patients with HN in the US (n= 606) and EU5 (France, Germany, Italy, Spain, UK; n= 1,000) was conducted between 7/2016 and 6/2017. Physicians randomly selected patient charts currently on an anti-cancer regimen and extracted data on patient demographics, disease status, treatment patterns, and biomarker status. ReSultS: Of the 1,606 HN patients included in this analysis, the US and EU5 had different gender distributions (percent male US: 68%, EU: 81%, p= < 0.01), but similar average ages (mean (SD) US: 62.86 (8.25), EU: 63.32 (8.81) between groups (p= 0.29). When identifying PD-L1 status between the countries, significantly more patients in the EU5 had never been tested (76%, US: 61%, p= < 0.01). Of those who were tested in the US (n= 238) and EU5 (n= 244), 63% of patients in the US were positive compared to only 35% in the EU5 (p= < 0.01). HPV results showed no differences in the testing rate (US: 89%, EU5: 91%, p= 0.54), but of those tested (US: 535, EU5: 908) significantly more HN patients tested HPV positive in the US (26%) than in the EU5 (16%, p= < 0.01). ConCluSionS: As new advanced therapies become available the importance of biomarker testing among HN cancer patients will continue to grow. Understanding the differences in how tests are used as well as patient test results by region is vital in the development and testing process.
The present case study was carried out to evaluate the role of Uttar basti with in tubal blockage, in order to establish it as a safer and cost effective Ayurvedic treatment modality. The criteria for selection of tubal blockage diagnosed in diagnostic laproscopy. Uttar basti was administered, after cessation of menstruation, to the screened patient through hematological, urinary and serological (HIV, VDRL, HBsAG) investigations. The result suggests that Uttar basti is a highly significant treatment for tubal blockage. Uttar basti is ideal local therapy is to be adopted in tubal block. Apamarga ksar tail is very good Vata kaphashamak guna and Lekhan properties, Taila is having the property to reach minute channels in body. Phala ghruta is best for all Yonirogas, also to reduce Dhaha which is due to Kshar tail.
The transformation of a female, from a woman to a mother is the happiest lifetime event, but this happiness is gained only after undergoing tremendous physical exertion during labour. The women become extremely debili- tated physically & mentally, after the delivery & there are more incidences of backache, feeling weakness etc. After the delivery of the baby, the placenta is expelled then the woman is termed as Sutika & the care is termed as Sutika-Paricharya. Mithyaachara during this period results in incurable diseases or diseases which are difficult to cure. After following proper Sutikopacharya (puerperal regimen) woman regains all the lost things and reaches pre-pregnancy status. The mode of Paricharya includes important therapies, nutritional diet &Swasthavrithapalana. The main achievements through Sutika-Paricharya are Garbhashayashuddhi, Dhatu- Paripurnata, Sthanya- Vriddhi,Punarnavekarana. So, the present study has been selected to review Charakokta- Sutika-Paricharya& its clinical importance. Keywords: Sutika, SutikaParicharya, SutikaParicharya, Mithyaachara
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.